Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
3
75%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_2

Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes

NCT05153070
completedphase_2

Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder

NCT04133233
completedphase_1

Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers

NCT03837093
completedphase_2

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

NCT02955615

Clinical Trials (4)

Showing 4 of 4 trials
NCT05153070Phase 2

Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes

Recruiting
NCT04133233Phase 2

Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder

Completed
NCT03837093Phase 1

Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers

Completed
NCT02955615Phase 2

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4